Total Payments
$171,007
2024 Payments
$37,340
Companies
12
Transactions
116
Medicare Patients
1,056
Medicare Billing
$162,366
Payment Breakdown by Category
Consulting$89,263 (52.2%)
Travel$46,224 (27.0%)
Other$24,750 (14.5%)
Research$7,280 (4.3%)
Food & Beverage$2,636 (1.5%)
Education$855.00 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,263 | 37 | 52.2% |
| Travel and Lodging | $46,224 | 26 | 27.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,875 | 5 | 11.6% |
| Unspecified | $7,280 | 4 | 4.3% |
| Honoraria | $4,375 | 2 | 2.6% |
| Food and Beverage | $2,636 | 40 | 1.5% |
| Education | $855.00 | 1 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $500.00 | 1 | 0.3% |
Payments by Type
General
$163,727
112 transactions
Research
$7,280
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62,889 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $56,521 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $13,735 | 18 | $0 (2022) |
| PFIZER INC. | $9,930 | 6 | $0 (2024) |
| ARRAY BIOPHARMA INC | $6,542 | 6 | $0 (2023) |
| Eisai Inc. | $5,625 | 3 | $0 (2021) |
| Incyte Corporation | $5,172 | 10 | $0 (2017) |
| Bristol-Myers Squibb Company | $3,081 | 1 | $0 (2019) |
| WHITEHALL INTERNATIONAL INC | $3,000 | 1 | $0 (2021) |
| Chugai Pharmaceutical Co., Ltd. | $2,280 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,340 | 13 | E.R. Squibb & Sons, L.L.C. ($21,245) |
| 2023 | $12,920 | 9 | E.R. Squibb & Sons, L.L.C. ($10,942) |
| 2022 | $12,360 | 7 | Novartis Pharmaceuticals Corporation ($3,713) |
| 2021 | $12,655 | 7 | Merck Sharp & Dohme Corporation ($4,500) |
| 2020 | $9,895 | 5 | Merck Sharp & Dohme Corporation ($4,000) |
| 2019 | $21,363 | 20 | Merck Sharp & Dohme Corporation ($8,421) |
| 2018 | $7,211 | 8 | E.R. Squibb & Sons, L.L.C. ($6,200) |
| 2017 | $57,263 | 47 | Merck Sharp & Dohme Corporation ($28,097) |
All Payment Transactions
116 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 10/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $345.47 | General |
| 10/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,151.00 | General |
| 09/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $11,512.80 | General |
| 08/19/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,355.00 | General |
| 08/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,271.19 | General |
| 06/26/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,355.00 | General |
| 06/02/2024 | PFIZER INC. | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $1,400.00 | Research |
| Study: BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/20/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB PF07265807 BINIMETINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,779.00 | General |
| 03/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,186.00 | General |
| 01/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,372.00 | General |
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $6,731.20 | General |
| 04/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $293.88 | General |
| 04/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $180.84 | General |
| 04/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $180.84 | General |
| 04/19/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $293.87 | General |
| 02/02/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $889.50 | General |
| 01/04/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $593.00 | General |
| 08/17/2022 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| 06/05/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $91.87 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENCORAFENIB PF07265807 BINIMETINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,680 | 2 |
| BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 279 | 583 | $310,220 | $48,806 |
| 2022 | 5 | 261 | 517 | $271,840 | $44,034 |
| 2021 | 6 | 255 | 496 | $252,835 | $41,531 |
| 2020 | 8 | 261 | 463 | $172,635 | $27,995 |
Total Patients
1,056
Total Services
2,059
Medicare Billing
$162,366
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 118 | 335 | $182,575 | $28,420 | 15.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 172 | $64,500 | $9,770 | 15.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $40,755 | $6,355 | 15.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 22 | $11,440 | $2,342 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 15 | $10,950 | $1,919 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 291 | $158,595 | $25,787 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 156 | $58,500 | $9,012 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $31,350 | $5,118 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 23 | $17,020 | $3,076 | 18.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 17 | $6,375 | $1,041 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 87 | 249 | $135,705 | $22,229 | 16.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 94 | 155 | $58,125 | $9,197 | 15.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 26 | 26 | $27,170 | $4,546 | 16.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 26 | $18,720 | $3,527 | 18.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 19 | 27 | $10,125 | $1,597 | 15.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 11 | 13 | $2,990 | $435.89 | 14.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 66 | 128 | $66,560 | $8,708 | 13.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 74 | 138 | $48,990 | $6,259 | 12.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 42 | $20,790 | $4,010 | 19.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 40 | 70 | $10,150 | $3,308 | 32.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 22 | 39 | $8,310 | $2,869 | 34.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $13,155 | $2,048 | 15.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 16 | 21 | $2,100 | $510.09 | 24.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 11 | 12 | $2,580 | $282.50 | 10.9% |
About Michael Postow
Michael Postow is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1487853594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Postow has received a total of $171,007 in payments from pharmaceutical and medical device companies, with $37,340 received in 2024. These payments were reported across 116 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($89,263).
As a Medicare-enrolled provider, Postow has provided services to 1,056 Medicare beneficiaries, totaling 2,059 services with total Medicare billing of $162,366. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Boston, MA
- Active Since 07/18/2007
- Last Updated 07/18/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1487853594
Products in Payments
- OPDIVO (Biological) $29,432
- BRAFTOVI (Drug) $17,630
- MEKINIST (Drug) $8,974
- Lenvima (Drug) $5,625
- TAFINLAR (Drug) $4,761
- TECENTRIQ (Biological) $2,145
- MEKTOVI (Drug) $1,595
- KEYTRUDA (Biological) $1,591
- LORBRENA (Drug) $150.00
- COTELLIC (Drug) $87.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M